Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Onward Medical   /   Forum Onward Medical geopend

Aandeel ONWARD MEDICAL BRU:ONWD.BL, NL0015000HT4

Laatste koers (eur) Verschil Volume
5,120   -0,020   (-0,39%) Dagrange 4,980 - 5,160 61.329   Gem. (3M) 59K

Forum Onward Medical geopend

Volgen
1.615 Posts
Pagina: «« 1 ... 76 77 78 79 80 81 | Laatste | Omlaag ↓
  1. Renno54 31 oktober 2024 07:48
    ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024
    Gepubliceerd op 31 oktober 2024 om 06:30

    EINDHOVEN, the Netherlands, Oct. 31, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its investigational ARC-EXs of 2024.

    "We are grateful for TIME’s recognition of the ARC-EX System, which has the potential to impact hundreds of thousands of people with spinal cord injury and impaired hand and arm function," said Dave Marver, CEO of ONWARD Medical. "SCI is a devastating injury that can change lives in an instant. We are hopeful ARC-EX Therapy is just the first of many innovative therapies ONWARD Medical can introduce for the benefit of the Spinal Cord Injury Community."

    TIME's annual list features 200 extraordinary innovations changing lives. The selection process involved nominations from TIME editors and correspondents around the world, with special attention paid to growing fields including healthcare, AI, and green energy. Each contender was evaluated based on key factors including originality, efficacy, ambition, and impact.

    The high-profile recognition from TIME arrives when many Americans are learning about the challenges associated with spinal cord injury from the feature film, Super/Man: The Christopher Reeve Story, currently in wide release in US theaters.
  2. Cybertom 31 oktober 2024 07:50
    ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024
    31 OCT 2024 06:30 CET

    ISSUER
    ONWARD MEDICAL

    EINDHOVEN, the Netherlands, Oct. 31, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its investigational ARC-EX System has been named one of TIME's Best Inventions of 2024.

    "We are grateful for TIME’s recognition of the ARC-EX System, which has the potential to impact hundreds of thousands of people with spinal cord injury and impaired hand and arm function," said Dave Marver, CEO of ONWARD Medical. "SCI is a devastating injury that can change lives in an instant. We are hopeful ARC-EX Therapy is just the first of many innovative therapies ONWARD Medical can introduce for the benefit of the Spinal Cord Injury Community."

    TIME's annual list features 200 extraordinary innovations changing lives. The selection process involved nominations from TIME editors and correspondents around the world, with special attention paid to growing fields including healthcare, AI, and green energy. Each contender was evaluated based on key factors including originality, efficacy, ambition, and impact.

    The high-profile recognition from TIME arrives when many Americans are learning about the challenges associated with spinal cord injury from the feature film, Super/Man: The Christopher Reeve Story, currently in wide release in US theaters.

    “The ARC-EX System provides hope for the millions of people suffering from spinal cord injury,” said Chet Moritz, PhD, Professor of Rehabilitation Medicine at the University of Washington. "Every day we work with people who share how much this advance could change their lives – to be able to grasp a toothbrush, hold a cup, or hug their children. With ARC-EX Therapy, we have seen people with no hand function regain the ability to play the guitar or paint, and return to living independently or raising a family without the need for caregiver assistance. We're so appreciative of TIME for acknowledging the inventive nature of this technology."

    Selection of the ARC-EX System follows this year’s published results of the Up-LIFT pivotal trial in Nature Medicine, which demonstrated significant improvements in upper limb strength and function in people with spinal cord injury. ONWARD Medical has submitted its regulatory application to the FDA for clearance of the ARC-EX System in the US and plans to launch the therapy later this year, pending a positive decision from FDA.

    SCI affects approximately seven million people globally, and nearly 300,000 people are living with SCI in the United States. For these individuals, the loss of arm and hand function is cited as the most devastating consequence, with more than 75% ranking it as their highest priority for recovery. According to the Up-LIFT trial results, 90% of SCI participants experienced improved strength or function, and 87% reported improvements in overall quality of life.1

    To learn more about ONWARD Medical’s commitment to partnering with the SCI Community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit ONWD.com.

    Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

    About ONWARD Medical

    ONWARD® Medical is a medical technology company creating therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of scientific discovery, preclinical, and clinical research conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy™, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA).

    ONWARD ARC Therapy is targeted, programmed spinal cord stimulation designed to be delivered by the Company’s external ARC-EX® or implantable ARC-IM® platforms. ARC Therapy can also be delivered by the Company’s ARC-BCI™ platform, which pairs the ARC-IM System with brain-computer interface (BCI) technology to restore movement after SCI with thought-driven control.

    Use of non-invasive ARC-EX Therapy significantly improved upper limb function after SCI in the global pivotal Up-LIFT trial, with results published by Nature Medicine in May 2024. The Company has submitted its regulatory application to the FDA for clearance of the ARC-EX System in the US and is preparing for regulatory submission in Europe. In parallel, the Company is conducting clinical studies with its ARC-IM Therapy, which demonstrated positive interim clinical outcomes for improved blood pressure regulation following SCI. Other ongoing clinical studies focus on using ARC-IM Therapy to address mobility after SCI and gait challenges in Parkinson’s disease as well as using the ARC-BCI platform to restore thought-driven movement of both upper and lower limbs after SCI.

    Headquartered in Eindhoven, the Netherlands, ONWARD Medical has a Science and Engineering Center in Lausanne, Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD).

    For more information, visit ONWD.com, and connect with us on LinkedIn and YouTube.

    For Media Inquiries:
    Aditi Roy, VP Communications
    media@onwd.com

    For Investor Inquiries:
    Amori Fraser, Finance Director
    investors@onwd.com
  8. forum rang 4 HOBBYMAN 31 oktober 2024 12:16
    quote:

    voda schreef op 31 oktober 2024 09:30:

    Kepler Cheuvreux verlaagt koersdoel Onward van 12,30 naar 10,00 euro
    Kepler Cheuvreux handhaaft koopadvies op Onward
    31-okt-2024 09:22
    Wat een onzin steeds die aanpassingen van koersdoelen bij dit soort bedrijven. Daar kan toch niemand iets mee.
  11. forum rang 10 voda 31 oktober 2024 15:02
    Technologie van Onward geprezen door TIME Magazine
    31-okt-2024 14:51

    Goedkeuring eind 2024 verwacht.

    (ABM FN-Dow Jones) Het ARC-EX-systeem van Onward is door het Amerikaanse TIME Magazine uitgeroepen tot een van de beste innovaties van 2024. Dit maakte het bedrijf donderdag bekend.

    "We zijn dankbaar voor TIME's erkenning van ARC-EX, dat het potentieel heeft om honderdduizenden mensen met een dwarslaesie en een verminderde hand- en armfunctie te beïnvloeden", aldus CEO Dave Marver van Onward in een toelichting.

    De jaarlijkse lijst van TIME bevat 200 buitengewone innovaties die levens veranderen.

    Analisten van Kepler Cheuvreux verwachten een voorspoedige lancering van ARC-EX in de Verenigde Staten. Een goedkeuring door toezichthouder FDA wordt tegen het einde van het jaar verwacht.

    Kepler verlaagde donderdag wel het koersdoel voor Onward van 12,30 naar 10,00 euro, na de kapitaalverhoging met 50 miljoen euro. Daarmee kan het bedrijf weer even vooruit tot in de eerste helft van 2027, aldus Kepler.

    Het aandeel Onward steeg donderdagmiddag met 2,4 procent tot 5,10 euro.

    Door: ABM Financial News.
  12. forum rang 5 K. Wiebes 31 oktober 2024 15:16
    time.com/7094714/onward-medical-arc-ex/

    By Jeff Wilser October 30, 2024 7:52 AM EDT
    Over 250,000 people in the U.S. alone live with spinal cord injuries. To help patients regain sensation and strength in their hands and arms, Onward Medical’s ARC-EX therapy uses electrical stimulation—applied externally with electrodes—to effectively boost the brain’s signals. A study in Nature showed that nine out of 10 patients using ARC-EX recovered some strength or functionality; it also found that the treatment can be effective for patients who had injuries decades earlier. “For most people with a spinal cord injury, there’s some [brain signal] conduction making it through the block, but not enough for movement,” says Dave Marver, CEO of Onward. “This device serves as an amplifier.”

    time.com/collection/best-inventions-2...
1.615 Posts
Pagina: «« 1 ... 76 77 78 79 80 81 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

ONWARD MEDICAL Nieuws

  1. Technologie van Onward geprezen door TIME Magazine
  2. Onward Medical haalt 50 miljoen euro op
  3. Onward lanceert nieuwe kapitaalverhoging
  4. Onward Medical vernieuwt bestuur
  5. Beursblik: Degroof Petercam ziet meer potentieel in koers Onward Medical
  6. Onward Medical verwerft exclusieve rechten op gedachtegestuurde technologie
  7. Onward Medical krijgt ook notering aan Euronext Parijs
  8. Onward Medical kondigt nieuwe succesvolle implantatie aan
  9. Iets meer in kas bij Onward Medical
  10. Belang Wellington in Onward gehalveerd